Akeso, Inc. (HKG:9926)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 74.45B |
| Revenue (ttm) | 2.26B |
| Net Income (ttm) | -547.53M |
| Shares Out | 897.56M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,497,201 |
| Average Volume | 17,512,814 |
| Open | 83.80 |
| Previous Close | 83.70 |
| Day's Range | 80.40 - 83.85 |
| 52-Week Range | 26.45 - 90.95 |
| Beta | 0.58 |
| RSI | 57.26 |
| Earnings Date | May 28, 2025 |
About Akeso
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovari... [Read more]
News
Why This Chinese Biotech Could Be Pharma's DeepSeek
The drugmaker's shares rallied after the release of its strong annual report, up by a cumulative 18% over the next three trading days Key Takeaways: Akeso's drug sales rose 25% last year to just above...
Akeso reports FY results
Chinese drug maker Akeso hailed as biotech's 'DeepSeek moment' amid US competition
Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed as the "DeepSeek moment" for China's drug industry, as biotech emerges as a...
Chinese drug maker Akeso hailed as biotech’s ‘DeepSeek moment’ amid US competition
Akeso’s immunotherapy drug allowed half of its patients to go 11.1 months without their condition worsening.
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs has upgraded BioNTech SE (NASDAQ: BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical development across multiple solid tumors. Data from Summit Therapeutics Inc . ...
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ: SMMT), noting the company’s initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed...